**Candida auris**: A drug-resistant fungus that spreads in healthcare facilities
A CDC message to laboratory staff

*Candida auris* is a fungus that causes serious infections and spreads in healthcare facilities. Laboratory staff, healthcare personnel, and infection preventionists can all help prevent it from spreading.

### Why is *Candida auris* a problem?

- **It causes serious infections.** *C. auris* can cause bloodstream and other types of invasive infections, particularly in patients in hospitals and nursing homes who have many medical problems. More than 1 in 3 patients die within a month of being diagnosed with an invasive *C. auris* infection.

- **It is often multidrug-resistant.** Antifungal medications commonly used to treat other *Candida* infections often don’t work for *C. auris*. Some *C. auris* isolates are resistant to all three major classes of antifungal medications.

- **It is becoming more common.** Although *C. auris* was just discovered in 2009, the number of cases has grown quickly. Since 2009, cases have been reported in dozens of countries, including the United States.

- **It is difficult to identify.** *C. auris* can be misidentified as other types of yeast unless specialized laboratory methods are used. Correctly identifying *C. auris* is critical for starting measures to stop its spread and prevent outbreaks.

- **It can spread and cause outbreaks in healthcare facilities.** Just like other multidrug-resistant organisms such as carbapenem-resistant Enterobacteriaceae (CRE) and methicillin-resistant *Staphylococcus aureus* (MRSA), *C. auris* can be transmitted in healthcare settings and cause outbreaks. It can colonize patients for many months, persist in the environment, and withstand some commonly used disinfectants in healthcare facilities.

### Early detection can help limit spread of *C. auris*.

### Prepare for *C. auris* identification

- Some phenotypic methods for yeast identification can misidentify *C. auris* as a number of different organisms.
  - *C. auris* is most often misidentified as *Candida haemulonii*, another rare yeast, but misidentifications depend on the lab methodology used.
  - Know whether the yeast identification method used in your laboratory misidentifies *C. auris* and, if so, what the possible misidentifications are. See [www.cdc.gov/fungal/candida-auris/recommendations.html](http://www.cdc.gov/fungal/candida-auris/recommendations.html) for common misidentifications by yeast identification method.
  - Misidentification can lead to inappropriate patient treatment and delay appropriate infection control precautions.

- There are no phenotypic characteristics that can easily distinguish *C. auris* from other *Candida* species.

- The most reliable way to identify *C. auris* is matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS).
  - If you have a MALDI-TOF MS in your lab, ensure that *C. auris* is included in the database.

- Molecular methods based on DNA sequencing can also identify *C. auris*. Accepted methods include sequencing of the D1-D2 region of the 28s ribosomal DNA (rDNA) or the internal transcribed spacer (ITS) region of rDNA.
Some labs have recently been successful implementing qPCR methods, which provide the fastest test results at this time.

Validate your instrument to confirm it can identify *C. auris*. If needed, use isolates from wwwn.cdc.gov/ARIsolateBank/.

Work with your facility’s infection preventionist to set up a plan for informing them about possible or confirmed *C. auris* and subsequent notification of public health authorities.

What should I do if *C. auris* is confirmed?

- Report possible or confirmed *C. auris* cases immediately to your facility’s infection prevention and control department and follow your facility’s process for reporting to public health departments.
- Conduct antifungal susceptibility testing.
- Look for other cases of *C. auris* in your facility:
  - Review microbiology records to find potentially missed cases.
  - Begin surveillance for *C. auris* from clinical specimens to identify new cases.

◊ *C. auris* is found in many body sites and fluids, including blood, urine, respiratory, and abdominal specimens.

◊ Consider identifying the species of *Candida* isolates from both sterile and non-sterile sites, even if this is not routine practice at your facility. Continue surveillance for at least one month or until there is no evidence of transmission.

More guidance on when to suspect *C. auris*, how to correctly identify *C. auris*, and suggested antifungal drug minimum inhibitory concentration (MIC) cutoff values are available on CDC’s webpage for

- Identification of *C. auris*: https://www.cdc.gov/fungal/diseases/candidiasis/recommendations.html

For more information, please contact the Centers for Disease Control and Prevention (CDC), National Center for Emerging and Zoonotic Infectious Diseases, Division of Foodborne, Waterborne, and Environmental Diseases.

1600 Clifton Road, NE, Mail Stop H24-9, Atlanta, GA 30329-4018

Telephone: 800-CDC-INFO (232-4636)  E-mail: candidaauris@cdc.gov  Web: https://www.cdc.gov/fungal

CS314875-B    Feb 13, 2020